sj-docx-1-msj-10.1177_13524585241234783 – Supplemental material for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Montalban, Xavier; Piasecka-Stryczynska, Karolina; Kuhle, Jens; Benkert, Pascal; Arnold, Douglas L; Weber, Martin S; Seitzinger, Andrea; Guehring, Hans; Shaw, Jamie; Tomic, Davorka; Hyvert, Yann; Harlow, Danielle E; Dyroff, Martin; Wolinsky, Jerry S

doi:10.25384/SAGE.25340382.v1

sj-docx-1-msj-10.1177_13524585241234783.docx (1.77 MB)

sj-docx-1-msj-10.1177_13524585241234783 – Supplemental material for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

journal contribution

posted on 2024-03-05, 05:13 authored by Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Martin S Weber, Andrea Seitzinger, Hans Guehring, Jamie Shaw, Davorka Tomic, Yann Hyvert, Danielle E Harlow, Martin Dyroff, Jerry S Wolinsky

Supplemental material, sj-docx-1-msj-10.1177_13524585241234783 for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study by Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Martin S Weber, Andrea Seitzinger, Hans Guehring, Jamie Shaw, Davorka Tomic, Yann Hyvert, Danielle E Harlow, Martin Dyroff and Jerry S Wolinsky in Multiple Sclerosis Journal